Delving into the Latest Updates on Visirna Biotechnology (Shanghai) Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Established in 2008, Visirna Biotechnology (Shanghai) provides one-stop comprehensive services ranging from early-stage structure-based drug development to commercial drug production for global innovative drug research and development companies. It has built several advanced technology platforms, including X-ray protein crystal technology, Cryo-EM, ASMS, SPR, HDX-MS, and computer-assisted drug design. Through its subsidiary, Langhua Pharmaceutical, Visirna provides a one-stop CMC/CDMO solution from preclinical development to commercial production. Additionally, Visirna focuses on discovering and investing in high-potential bio-pharmaceutical startups, employing a unique business model of Equity-for-Service (EFS) to address unmet clinical needs.

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

siRNA	3

Top 5 Target	Count

ANGPTL3(Angiopoietin like 3)	1
17β-HSD13(17-beta-hydroxysteroid dehydrogenase 13)	1
APOC3(Apolipoprotein C-III)	1

Evaluate the efficacy of VSA006 injection in the treatment of NASH patients. Evaluate the safety and tolerability of VSA006 injection in NASH patients. Evaluate the pharmacokinetic (PK) characteristics of VSA006 injection in NASH patients. Explore the immunogenicity characteristics of VSA006 injection.

Start Date08 Mar 2024

Sponsor / Collaborator

Visirna Biotechnology (Shanghai) Co., Ltd.

CTR20231418 / Active, not recruitingPhase 3

一项在中国家族性乳糜微粒血症综合征成人患者中评价VSA001注射液有效性和安全性的III期临床研究

[Translation] A Phase III clinical study evaluating the efficacy and safety of VSA001 injection in Chinese adult patients with familial chylomicronemia syndrome

该研究的主要目的是在中国家族性乳糜微粒血症综合征（FCS）成人患者中评价VSA001的有效性和安全性。

[Translation]

The primary objective of the study is to evaluate the efficacy and safety of VSA001 in Chinese adult patients with familial chylomicronemia syndrome (FCS).

Start Date10 Jul 2023

Sponsor / Collaborator

Visirna Therapeutics HK Limited

[+2]

CTR20231390 / CompletedPhase 1

一项在中国健康成年志愿者中评价VSA001注射液单次给药的安全性、耐受性、药代动力学和药效学的随机、双盲、安慰剂对照I期临床研究

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of VSA001 injection in healthy adult volunteers in China

一项在中国健康成年志愿者中评价VSA001注射液安全性、耐受性、药代动力学和药效学特征的随机、双盲、安慰剂对照、单次给药I期临床研究。

[Translation]

A randomized, double-blind, placebo-controlled, single-dose Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VSA001 injection in healthy adult volunteers in China.

Start Date17 May 2023

Sponsor / Collaborator

Visirna Therapeutics HK Limited

[+2]

100 Clinical Results associated with Visirna Biotechnology (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Visirna Biotechnology (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with Visirna Biotechnology (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Visirna Biotechnology (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

VSA-006 ( 17β-HSD13 )	Nonalcoholic Steatohepatitis More	Phase 2
Zodasiran ( ANGPTL3 )	Dyslipidemias More	Phase 2
Plozasiran ( APOC3 )	Hypertriglyceridemia More	Phase 2